Vein access device effective in early study:
This article was originally published in Clinica
An implantable device which provides access to the veins of haemodialysis patients has worked well in a preliminary study of patients at the Austin Diagnostic Center in Texas. The LifeSite device, a stainless steel and titanium alloy valve implanted just under the skin, was developed by Topsfield, Massachusetts-based VascA. According to the results of the study, it allowed increased blood flow and was free from thrombosis in all ten patients. The device, which is already sold in Canada and Europe, is designed as an alternative to fistulas, synthetic grafts and dialysis catheters.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.